- Company
- KPBMA visits Boston...expands exchanges with MIT, etc.
- by Chon, Seung-Hyun Nov 18, 2022 06:04am
- On the 17th, Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) announced that its delegation had visited Boston, US to network with local companies and institutions. Hee-Mok Won, Director of KPBMA, Sung-Tae Yoon, Chairman of KPBMA, and other representatives of Korea’s pharmaceutical and bio business attended the exec
- Company
- Generic companies won 9 out of 10 patent disputes
- by Kim, Jin-Gu Nov 17, 2022 05:54am
- In a patent dispute between the original company and the generic company over generic for exclusivity, a study found that the generic company's first trial winning rate reached 88.5%. Lee Myung-hee, a senior researcher at the KIIP, announced the results of the impact assessment of the licensing patent-linked system at the 2022 Pharmaceutic
- Company
- Announcement of commercialization of oral insulin
- by Eo, Yun-Ho Nov 17, 2022 05:54am
- Expectations are rising for PO use for injectable insulin. Medicox recently signed an exclusive distribution contract with Israeli pharmaceutical company Oramed Pharmaceuticals following the introduction of oral insulin technology. As a result, Medicox will be able to distribute Oramed's oral insulin candidate "ORMD-0801" for 10 years in Kore
- Company
- The aftermath of stricter generic regulations?
- by Kim, Jin-Gu Nov 16, 2022 06:11am
- It was found that the number of applications for generic for exclusivity decreased sharply. Experts agree that the implementation of the 1+3 system has affected the decrease in the number of generic for exclusivity applications. Lee Myung-hee, a senior researcher at KIIP, introduced the number of generic for exclusivity applications in 2020 a
- Company
- Gavreto applies for reimbursement following Retevmo
- by Eo, Yun-Ho Nov 16, 2022 06:10am
- In line with the progress made in Retevmo’s reimbursement review process, its competitor Gavreto was also found to have started its reimbursement process in Korea. According to industry sources, Roche Korea submitted an application for the reimbursement of its RET (Rearranged during transfection) gene fusion targeted therapy Gavreto (pr
- Company
- Impinzi's indication of biliary tract cancer
- by Nov 16, 2022 06:10am
- AstraZeneca Korea announced on the 14th that its immune anticancer drug "Imfinzi" has received additional approval from the Ministry of Food and Drug Safety for biliary tract cancer. Imfinzi can be used as a combination therapy with Gemcitabine and Cisplatin in the primary treatment of patients with locally advanced or metastatic biliary t
- Company
- Tecentriq approved as adjuvant treatment for NSCLC
- by Nov 15, 2022 05:38am
- On the 14th, Roche Korea announced that its anti-PD-L1 immuno-oncology drug Tecentriq (atezolizumab) was approved as adjuvant therapy following resection in patients with early-stage non-small-cell-lung cancer, and became the first immunotherapy to receive approval for the indication. Tecentriq may now be used as an adjuvant treatment fol
- Company
- CR of AML new drug candidates is identified in Phase 1/2
- by Kim, Jin-Gu Nov 15, 2022 05:38am
- Hanmi Pharmaceutical announced on the 14th that it has confirmed cases of complete response (CR) in various dose groups as a result of phase 1/2 clinical trials of Tuspetinib (HM43239), which is being developed as an AML treatment. Aptose was recently introduced at the KOL webinar, "As a result of the global phase 1/2 for patients with recurr
- Company
- Merck KGaA has appointed Christoph Hamann
- by Nov 15, 2022 05:38am
- Merck Biopharma Korea announced on the 10th that it has appointed Christoph Hamann as the new general representative of its business unit. Harman served as general manager of Merck Biopharma in Malaysia, Singapore, and Brunei, and as Managing Director in Malaysia. Since joining Merck in 2009, he has built various careers through strategic and
- Company
- Adding AUS as a drug price reference country raise concerns
- by Nho, Byung Chul Nov 14, 2022 06:07am
- The health authorities are known to be considering including Canada and Australia as reference countries for drug pricing reevaluations. Currently, the Ministry of Health and Welfare, Health Insurance Review and Assessment Service, and the National Health Insurance Service refer to drug prices of G7 countries - US, UK, Germany, Switz
